HCAT
Health Catalyst, Inc.
$1.93
-0.52%
$143.4M
No data for this timeframe.
Vol
Market Cap$143.4M
Cap SizeMicro Cap
Analyst ConsensusBuy (50%)
Inst. Holders7 funds
Inst. Value$14.4M
Inst. Activity3 buys / 2 sells
SEC Reports6
Press Releases1
Exchange Nasdaq·Sector Services-Computer Programming, Data Processing, Etc.·Inc. DE·CIK 0001636422·Prev Close $1.94
Recent Activity
Jun 4, 2026
SEC
Health Catalyst signed a definitive agreement to sell its Vitalware mid-revenue cycle business unit to Med-Metrix for $1
8-K — Impact 7/10
Jun 4, 2026
contract
Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation
Health Catalyst today announced it has signed a definitive agreement to divest Vitalware, its mid-re
Jun 3, 2026
SEC
Health Catalyst filed a DEFA14A (additional definitive proxy soliciting material) on June 3, 2026. The filing contains b
DEFA14A — Impact 2/10
Jun 1, 2026
Insider
Larson-Green Julie sold 12,710 shares
Director @ $0.00 ($0.00)
Jun 1, 2026
Insider
Landry Benjamin sold 13,779 shares
General Counsel @ $1.37 ($18.9K)
Jun 1, 2026
Insider
Alger Jason sold 18,804 shares
Chief Financial Officer @ $1.37 ($25.8K)
May 11, 2026
SEC
Health Catalyst reported Q1 2026 revenue of $70.8M, down 11% YoY, with a GAAP net loss of $111M including a $95.5M goodw
8-K — Impact 7/10
Inst.
FMR LLC — ADD
348,716 shares ($833.4K)
Price Targets
$1.75
-9.3% upside
Sell
Current $1.93
Low $1.00
Median $1.88
High $2.00
6 analysts
$1.00
$2.00
Analyst Ratings
3Strong Buy
4Buy
7Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 12, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight → Equal-Weight |
| Mar 18, 2026 | Wells Fargo | DOWNGRADE | Overweight → Equal-Weight |
| Mar 13, 2026 | Citigroup | MAINTAIN | Neutral → Neutral |
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Mar 13, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.03 ▼ -25.9% | $0.01 — $0.05 | -37% YoY | 6 |
| Next Q | $-0.00 ▼ -101.3% | $-0.03 — $0.07 | -101% YoY | 5 |
| Current FY | $0.04 ▼ -70.4% | $-0.05 — $0.22 | -78% YoY | 7 |
| Next FY | $0.09 ▼ -41.8% | $-0.07 — $0.52 | 137% YoY | 6 |
Latest Reports
BULLISH
8-K
7/10
Health Catalyst signed a definitive agreement to sell its Vitalware mid-revenue cycle business unit to Med-Metrix for $1
Jun 4, 2026
NEUTRAL
DEFA14A
2/10
Health Catalyst filed a DEFA14A (additional definitive proxy soliciting material) on June 3, 2026. The filing contains b
Jun 3, 2026
NEUTRAL
Press
2/10
Health Catalyst appointed Steve Nelson, President of Aetna, to its Board of Directors, effective May 1, 2026. This follo
Apr 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $10.6M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.3M | NEW |
| FMR LLC | $833.4K | ADD |
| MORGAN STANLEY | $798.2K | ADD |
| BANK OF AMERICA CORP | $436.9K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Larson-Green Julie | A | $0.00 |
| Jun 1, 2026 | Landry Benjamin | F | $18.9K |
| Jun 1, 2026 | Alger Jason | F | $25.8K |
| Jun 1, 2026 | Llewelyn Linda | F | $11.7K |
| Jun 1, 2026 | Albert Benjamin | F | $460.39 |
7 institutional holders with $14.4M total value (6,027,261 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, FMR. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,434,387 | $10.6M | 73.6% | — |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 546,967 | $1.3M | 9.1% | NEW |
| 3 | FMR LLC | 348,716 | $833.4K | 5.8% | ADD +27.8% |
| 4 | MORGAN STANLEY | 333,955 | $798.2K | 5.5% | ADD +37.8% |
| 5 | BANK OF AMERICA CORP /DE/ | 182,807 | $436.9K | 3.0% | DOUBLED +127.5% |
| 6 | TWO SIGMA INVESTMENTS, LP | 100,097 | $239.2K | 1.7% | TRIM -43.5% |
| 7 | WELLS FARGO & COMPANY/MN | 80,332 | $192.0K | 1.3% | ADD +76.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 272,933 | 348,716 | +27.8% | $833.4K | 2025-Q4 |
| MORGAN STANLEY | ADD | 242,317 | 333,955 | +37.8% | $798.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 80,348 | 182,807 | +127.5% | $436.9K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 177,091 | 100,097 | -43.5% | $239.2K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 45,869 | 0 | -100.0% | $0.00 | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 42,426 | 177,091 | +317.4% | $504.7K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 49,400 | 87,283 | +76.7% | $248.8K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 45,869 | — | $130.7K | 2025-Q3 |
| UBS Group AG | TRIM | 631,783 | 179,427 | -71.6% | $676.4K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 153,317 | 98,188 | -36.0% | $370.2K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 42,426 | — | $159.9K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 2,733,455 | 631,783 | -76.9% | $2.9M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 255,292 | 189,026 | -26.0% | $856.3K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 295,628 | 169,141 | -42.8% | $766.2K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 70,208 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 196,591 | 295,628 | +50.4% | $2.1M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 30,904 | 39,355 | +27.3% | $278.2K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 573,061 | — | $4.7M | 2024-Q3 |
| MORGAN STANLEY | TRIM | 443,143 | 306,387 | -30.9% | $2.5M | 2024-Q3 |
6 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Larson-Green Julie | Director | A | 12,710 | $0.00 | $0.00 |
| Jun 1, 2026 | Landry Benjamin | General Counsel | F | 13,779 | $1.37 | $18.9K |
| Jun 1, 2026 | Alger Jason | Chief Financial Officer | F | 18,804 | $1.37 | $25.8K |
| Jun 1, 2026 | Llewelyn Linda | Chief People Officer | F | 8,519 | $1.37 | $11.7K |
| Jun 1, 2026 | Albert Benjamin | CEO | F | 336 | $1.37 | $460.39 |
| May 1, 2026 | Albert Benjamin | CEO | F | 310 | $1.35 | $416.95 |
| May 1, 2026 | Nelson Steven H | Director | A | 154,808 | $0.00 | $0.00 |
| Apr 29, 2026 | Albert Benjamin | CEO | A | 1,124 | $0.00 | $0.00 |
| Mar 10, 2026 | Albert Benjamin | CEO | F | 70,455 | $1.85 | $130.2K |
| Mar 2, 2026 | Alger Jason | Chief Financial Officer | F | 26,970 | $1.66 | $44.8K |
| Mar 2, 2026 | Llewelyn Linda | Chief People Officer | F | 13,836 | $1.66 | $23.0K |
| Mar 2, 2026 | Landry Benjamin | General Counsel | F | 20,838 | $1.66 | $34.6K |
| Feb 26, 2026 | Alger Jason | Chief Financial Officer | F | 7,522 | $1.75 | $13.1K |
| Feb 26, 2026 | Albert Benjamin | CEO | F | 13,304 | $1.75 | $23.3K |
| Feb 26, 2026 | Landry Benjamin | General Counsel | F | 6,317 | $1.75 | $11.0K |
| Feb 26, 2026 | Llewelyn Linda | Chief People Officer | F | 4,471 | $1.75 | $7.8K |
| Feb 25, 2026 | Landry Benjamin | General Counsel | A | 289,000 | $0.00 | $0.00 |
| Feb 25, 2026 | Albert Benjamin | CEO | A | 930,000 | $0.00 | $0.00 |
| Feb 25, 2026 | Alger Jason | Chief Financial Officer | A | 507,500 | $0.00 | $0.00 |
| Feb 25, 2026 | Llewelyn Linda | Chief People Officer | A | 191,500 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 3 neutral. Avg impact: 4.5/10.
BULLISH
8-K
7/10
Health Catalyst signed a definitive agreement to sell its Vitalware mid-revenue cycle business unit
Jun 4, 2026
NEUTRAL
DEFA14A
2/10
Health Catalyst filed a DEFA14A (additional definitive proxy soliciting material) on June 3, 2026. T
Jun 3, 2026
BEARISH
8-K
7/10
Health Catalyst reported Q1 2026 revenue of $70.8M, down 11% YoY, with a GAAP net loss of $111M incl
May 11, 2026
NEUTRAL
PRESS-RELEASE
2/10
Health Catalyst announced Q1 2026 earnings release date of May 11, 2026, after market close. No fina
May 1, 2026
NEUTRAL
10-K/A
3/10
This is a routine 10-K/A amendment filed solely to add Part III items (director/officer info, execut
Apr 30, 2026
BEARISH
8-K
6/10
Health Catalyst announced a 9% workforce reduction and elimination of 100 open roles as part of 'Pro
Apr 27, 2026
Current analyst consensus: Hold (50% buy). Based on 14 analysts: 3 strong buy, 4 buy, 7 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$1.75 mean target
-9.3% upside
Sell (3.00)
$1.00 Low
$2.00 High
| Metric | Value |
|---|---|
| Current Price | $1.93 |
| Target Low | $1.00 |
| Target Mean | $1.75 |
| Target Median | $1.88 |
| Target High | $2.00 |
| # Analysts | 6 |
| Recommendation | Sell (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.03 | $0.01 | $0.05 | -36.5% | -25.9% | 2↑ 1↓ | $0.1B | -14.6% | 6 |
| Next Q 2026-09-30 |
$-0.00 | $-0.03 | $0.07 | -100.7% | -101.3% | 0↑ 3↓ | $0.1B | -17.5% | 5 |
| Current FY 2026-12-31 |
$0.04 | $-0.05 | $0.22 | -78.4% | -70.4% | 0↑ 4↓ | $0.3B | -15.5% | 7 |
| Next FY 2027-12-31 |
$0.09 | $-0.07 | $0.52 | 137.4% | -41.8% | 2↑ 4↓ | $0.2B | -7.4% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.025 | |
| 7d ago | $0.034 | -0.009 |
| 30d ago | $0.034 | -0.009 |
| 60d ago | $0.039 | -0.014 |
| 90d ago | $0.088 | -0.062 |
6 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 12, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight | Equal-Weight |
| Mar 18, 2026 | Wells Fargo | DOWNGRADE | Overweight | Equal-Weight |
| Mar 13, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 13, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight | Equal-Weight |
| Mar 13, 2026 | Stifel | MAINTAIN | Hold | Hold |
| Mar 13, 2026 | Cantor Fitzgerald | MAINTAIN | Neutral | Neutral |
| Jan 9, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 7 | 0 | 0 | 50% | |
| May 1, 2026 | 3 | 4 | 8 | 0 | 0 | 47% | |
| Apr 1, 2026 | 3 | 4 | 8 | 0 | 0 | 47% | |
| Mar 1, 2026 | 3 | 5 | 9 | 0 | 0 | 47% | |
| Feb 1, 2026 | 3 | 5 | 9 | 0 | 0 | 47% | |
| Jan 1, 2026 | 3 | 5 | 9 | 0 | 0 | 47% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
contract
Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation
Health Catalyst today announced it has signed a definitive agreement to divest Vitalware, its mid-revenue cycle business, to Med-Metrix for $147 milli
May 12, 2026
earnings_calendar
HCAT Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
earnings_calendar
HCAT Q1 2026 Earnings Scheduled — 2026-05-11
May 5, 2026
earnings_calendar
HCAT Q1 2026 Earnings Scheduled — 2026-05-05
May 4, 2026
short_volume
Short Volume: HCAT — 74.9% short (0.6M / 0.9M)
Short: 639,323 | Exempt: 6,047 | TRF Vol: 853,987 | Short Ratio: 74.9% | Off-exchange volume (dark pool + OTC)
May 1, 2026
earnings
Health Catalyst to Announce First Quarter 2026 Operating Results and Host Conference Call on Monday, May 11, 2026
<p align="left">SALT LAKE CITY, May 01, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence
Apr 30, 2026
leadership
Health Catalyst Appoints Steve Nelson, President of Aetna, to Its Board of Directors
Health Catalyst, Inc. announced that Steve Nelson has been appointed to its Board of Directors, effective May 1, 2026.
Mar 12, 2026
earnings
Health Catalyst Reports Fourth Quarter and Year End 2025 Results
<p align="justify">SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of
Mar 12, 2026
earnings_calendar
HCAT Q4 2025 Earnings After Market Close — 2026-03-12
Mar 3, 2026
earnings_calendar
HCAT Q4 2025 Earnings After Market Close — 2026-03-03
Mar 2, 2026
earnings_calendar
HCAT Q4 2025 Earnings After Market Close — 2026-03-02